The company Dermagnostix GmbH offers innovative molecular diagnostic solutions for dermatology. The young company was founded in 2021 as a spin-off of the Hahn-Schickard Institute in Freiburg as well as the Helmholtz Zentrum München and the Technical University of Munich.
Dermagnostix develops and markets PsorX, the first test worldwide that - based on the gene expression of NOS2 and CCL27 - detects the molecular signature of psoriasis and eczema with very high sensitivity and specificity, thus enabling a reliable differential diagnosis of these diseases.
This unique test is performed on the LabDisk, a disposable cartridge that contains all the reagents needed to perform the test. By compressing a complete laboratory in the LabDisk, all assay steps from sample purification to signal detection are fully automated in the LabDisks. The modular design of the centrifugal microfluidic units allows flexible adaptation of the LabDisks to the requirements of each assay and sample material.
At Dermagnostix, experts in dermatology, molecular biology, microfluidics and artificial intelligence have joined forces to help patients suffering from skin diseases, which are associated with severe suffering and stigmatization, to receive accurate diagnoses. The company is located in Freiburg, Germany.